**Name of Journal: *World Journal of Virology***

**Manuscript NO: 34045**

**Manuscript Type: Field of Vision**

**Additional attention to combination antiretroviral therapy-related lipodystrophy**

Kobayashi N *et al*. cART-related lipodystrophy

**Norihiko Kobayashi,** **Masako Nakahara,** **Masako Oka, Kumiko Saeki**

**Norihiko Kobayashi, Masako Nakahara, Masako Oka, Kumiko Saeki,** Department of Disease Control, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

**Author contributions:** Kobayashi N, Nakahara M and Oka M collected the materials and wrote the manuscript; Saeki K supervised the publication of this commentary.

**Conflict-of-interest statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Kumiko Saeki, MD, PhD,** Department of Disease Control, Research Institute, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. saeki@ri.ncgm.go.jp

**Telephone:** +81-3-32027181

**Fax:** +81-3-32071038

**Received:** March 23, 2017

**Peer-review started:** March 24, 2017

**First decision:** May 19, 2017

**Revised:** July 21, 2017

**Accepted:** August 3, 2017

**Article in press:**

**Published online:**

**Abstract**

The occurrence of lipodystrophy in patients taking anti-human immunodeficiency virus (HIV) medications is a serious problem as it is irreversible even after drug withdrawal. Although it was first recognized in patients taking proteinase inhibitors, other types of anti-HIV agents can also cause lipodystrophy. In a recent publication by Jones *et al* entitled “Highly active antiretroviral therapy (HAART) dysregulates proliferation and differentiation of human pre-adipocytes” in World Journal of Virology, it was reported that simultaneous treatment of human subcutaneous adipocytes with anti-HIV drugs with different mechanisms of action synergistically exerted anti-adipogenesis effects *in vitro*, warning us to take utmost care in every case receiving combination antiretroviral therapy (cART). For elucidation of the molecular basis for cART-related lipodystrophy, multi-faceted approaches should be taken, based on a deeper understanding of the development and organization of adipose tissues.

**Key words:** Combination antiretroviral therapy, Lipodystrophy; Protease inhibitor; Reverse transcriptase inhibitor; Human immunodeficiency virus

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Development of lipodystrophy in patients receiving combination antiretroviral therapy (cART) has been a serious problem. Although it was first reported in patients taking proteinase inhibitors, other types of anti-human immunodeficiency virus (HIV) agents also cause lipodystrophy. A recent publication in World Journal of Virology reported unexpected synergism among anti-HIV drugs with different mechanisms of action in inhibiting adipogenesis *in vitro*. To elucidate the molecular basis for cART-related lipodystrophy, multi-faceted approaches should be taken with a deeper understanding of the development and organization of adipose tissues.

Kobayashi N, Nakahara M, Oka M, Saeki K. Additional attention to combination antiretroviral therapy-related lipodystrophy. *World J Virol* 2017; In press

**COMMENTARY ON A RECENT ARTICLE ON COMBINATION ANTIRETROVIRAL THERAPY-RELATED LIPODYSTROPHY**

***Lipodystrophy is a serious problem in patients receiving combination antiretroviral therapy***

The development of combination antiretroviral therapy (cART), where more than two types of anti-HIV agents with different mechanisms of action are used, has greatly improved the prognosis of acquired immune deficiency syndrome (AIDS) by reducing mortality rates and suppressing opportunistic infections. With the extension of the administration period, however, it has becoming increasingly important to take effective measures to control the side effects of cART. The major adverse conditions caused by anti-HIV agents are lipodystrophy, atherosclerosis, eruption, osteoporosis and lactic acidosis. Since the pathophysiology of cART-related lipodystrophy is an irreversible process, elucidation of the mechanism how anti-HIV agents induce lipodystrophy is a matter of particular importance. In the current commentary, possible mechanisms of cART-related lipodystrophy are discussed by referring a recent paper by Jones *et al*[1] in World Journal of Virology, which reported an unexpected synergy among anti-HIV drugs with different mechanisms of action in inhibiting proliferation and differentiation of human preadipocytes *in vitro* (Figure 1).

***Organization of adipose tissues***

Adipose tissues consist of parenchymal cells (*i.e.,* adipocytes and their progenitors) and non-parenchymal cells (*i.e.,* non-adipocyte lineage cells) (Figure 2) and disorders of any of these components may result in the development of lipodystrophy. Caso *et al*[2] previously reported that two proteinase inhibitors, ritonavir (RTV) and atazanavir (ATV), inhibited the proliferation and differentiation of human subcutaneous preadipocytes *in vitro*. In a recent paper, the same group showed that protease inhibitors (RTV, ATV), nucleoside/nucleotide reverse transcriptase inhibitors [emtricitabine (FTC), tenofovir (TDF)] and a non-nucleoside reverse transcriptase inhibitor (efavirenz (EFV) ) synergistically inhibited proliferation and differentiation/maturation of human preadipocytes obtained from subcutaneous fat depots[1]. It is surprising that synergism exists among drugs with completely different action mechanisms. Although the molecular basis of this synergism remains unknown, the finding has sounded the alarm about the risk of unexpected occurrence of lipodystrophy in cART-receiving patients.

In addition to affecting parenchymal cells, anti-HIV agents may impair the functions of non-parenchymal cells, which consist of mesenchymal stem cells (MSCs), vascular endothelial cells (VEC), pericytes/vascular smooth muscle cells, resident macrophages (M2) and inflammatory macrophages (M1) (Figure 2). Among these, VECs may be of most interest for the following three reasons: First, anti-HIV agents reportedly induce oxidative damage to VECs[3], which is considered to be one of the causes of development of cART-related atherosclerosis. Atherosclerosis in adipose tissue vasculatures within specific regions of subcutaneous fat depots may cause local ischemia, resulting in degeneration/loss of adipose tissues in specific areas such as the face and limbs. However, the reason why the face and limbs are commonly affected by cART-related lipodystrophy remains unknown. Secondly, VECs in adipose tissues (A-VEC) is known as one of the ancestors of adipocytes[4,5]. Recurrent damage to A-VECs by anti-HIV agents may reduce the population size of adipocyte precursors, which might, in turn, result in the occurrence of lipodystrophy after a time. Lastly, it is accepted that A-VECs have distinctive characteristics compared with VECs of other tissues; for example, VECs of white adipose tissues exhibit specific antigenicity[6]. Moreover, it was recently reported that poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate (PMB)-coated carbon nanotubes specifically accumulated in the capillary endothelial cells of adipose tissues[7]. Even under conditions where anti-HIV drugs do not cause oxidative damage to A-VEC, they might possibly affect specific functions of A-VEC, thus promoting the development of lipodystrophy.

Other non-parenchymal cells could also be the targets of cART. The MSCs can be precursors of preadipocytes, and pericytes/vascular smooth muscle cells are recognized as an equivalent of MSCs[8], although a recent paper by Guimarães-Camboa *et al*[9] has challenged this idea. Similarly to A-VECs, pericytes/vascular smooth muscle cells in adipose tissues are considered as one of the ancestors of adipocytes[5]. It is known that white adipose tissues are particularly rich in M2 macrophages, which provide a niche for preadipocytes[10]. On the other hand, M1 inflammatory macrophages are recruited into adipose tissues from the bone marrow when adipocytes undergo degeneration. Defects in the clearance of degenerative adipocytes may create pathological states of adipose tissues, which possibly lead to the development of lipodystrophy.

Although the critical target cells remain undetermined, the etiology of cART-related lipodystrophy should be investigated from multiple perspectives.

***Possible mechanisms of cART-lipodystrophy***

The incidence of lipodystrophy was first recognized in patients receiving protease inhibitors[11,12] and more than half of affected patients reportedly take these drugs[13]. In addition to suppressing growth and differentiation of preadipocytes[1], protease inhibitors reportedly exert multifactorial effects on adipocytes including impairment of mitochondrial functions[14], changes in the gene expression related to ER-stress and lipid droplet formation[14] and even an induction of mitophagy[15]. cART-related dystrophy is not restricted to protease inhibitor-receiving cases[16]. Patients with cART-related dystrophy are relatively healthy[13], although hypertriglyceridemia and insulin resistance may be present[11-13,16-19]. Nevertheless, cART-related dystrophy is a crucial issue to be addressed, since loss of fat depots frequently occurs in the face and limbs and fat wasting of the face considerably reduces quality of life. The reason why adipose tissues in the distal parts of the body are commonly affected by cART-related dystrophy remains elusive. In some cases, subcutaneous fat depots are reciprocally accumulated in the central parts of body including the abdomen, trunk and neck. Since plasma cortisol values are reportedly within the normal range, central fat accumulation cannot be attributed to hypercortisolism[16]. Interestingly, adipose tissue-specific Dicer knockout (ADicerKO) mice reportedly exhibit a phenotype that bears a close resemblance to cART-related lipodystrophy[20]. They even show buffalo hump-like phenotypes, in which brown adipose tissues (BAT) are substantially enlarged and degenerated into white adipose tissue (WAT) accumulations[20]. Since BATs are mainly located in the neck and upper back areas in mice and humans, central fat accumulation in cART-related lipodystrophy might possibly be associated with abnomal lipid accumulation in BATs.

In summary, the etiology of cART-related lipodystrophy remains largely unknown and further investigations will be required to elucidate its developmental mechanisms.

**REFERENCES**

1. **Jones E,** Mazirka P, McNurlan MA, Darras F, Gelato MC, Caso G. Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes. *World J Virol* 2017; In press
2. **Caso G**, Mileva I, McNurlan MA, Mynarcik DC, Darras F, Gelato MC. Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation. *Antiviral Res* 2010; **86**: 137-143 [PMID: 20153378]
3. **Jiang B**, Hebert VY, Li Y, Mathis JM, Alexander JS, Dugas TR. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. *Toxicol Appl Pharmacol* 2007; **224**: 60-71 [PMID: 17669453 DOI: 10.1016/j.taap.2007.06.010]
4. **Tran KV**, Gealekman O, Frontini A, Zingaretti MC, Morroni M, Giordano A, Smorlesi A, Perugini J, De Matteis R, Sbarbati A, Corvera S, Cinti S. The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells. *Cell Metab* 2012; **15**: 222-229 [PMID: 22326223 DOI: 10.1016/j.cmet.2012.01.008]
5. **Gupta RK**, Mepani RJ, Kleiner S, Lo JC, Khandekar MJ, Cohen P, Frontini A, Bhowmick DC, Ye L, Cinti S, Spiegelman BM. Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells. *Cell Metab* 2012; **15**: 230-239 [PMID: 22326224 DOI: 10.1016/j.cmet.2012.01.010]
6. **Kolonin MG**, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. *Nat Med* 2004; **10**: 625-632 [PMID: 15133506 DOI: 10.1038/nm1048]
7. **Yudasaka M**, Yomogida Y, Zhang M, Tanaka T, Nakahara M, Kobayashi N, Okamatsu-Ogura Y, Machida K, Ishihara K, Saeki K, Kataura H. Near-Infrared Photoluminescent Carbon Nanotubes for Imaging of Brown Fat. *Sci Rep* 2017; **7**: 44760 [PMID: 28317858 DOI: 10.1038/srep44760]
8. **Crisan M**, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Péault B. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 2008; **3**: 301-313 [PMID: 18786417 DOI: 10.1016/j.stem.2008.07.003]
9. **Guimarães-Camboa N**, Cattaneo P, Sun Y, Moore-Morris T, Gu Y, Dalton ND, Rockenstein E, Masliah E, Peterson KL, Stallcup WB, Chen J, Evans SM. Pericytes of Multiple Organs Do Not Behave as Mesenchymal Stem Cells In Vivo. *Cell Stem Cell* 2017; **20**: 345-359.e5 [PMID: 28111199 DOI: 10.1016/j.stem.2016.12.006]
10. **Nawaz A,** Aminuddin A, Kado T, Takikawa A, Yamamoto S, Tsuneyama K, Igarashi Y, Ikutani M, Nishida Y, Nagai Y, Takatsu K, Imura J, Sasahara M, Mori H, Matsumoto M, Nakagawa T, Norihiko K, Saeki K, Usui I, Fujisaka S, Tobe K. CD206+ cells regulate glucose metabolism and inhibit proliferation of adipocyte progenitors through TGFβ signaling. *Nat Commun*; In press
11. **Viraben R**, Aquilina C. Indinavir-associated lipodystrophy. *AIDS* 1998; **12**: F37-F39 [PMID: 9583592]
12. **Carr A**, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. *AIDS* 1998; **12**: F51-F58 [PMID: 9619798]
13. **Garg A**. Acquired and inherited lipodystrophies. *N Engl J Med* 2004; **350**: 1220-1234 [PMID: 15028826 DOI: 10.1056/NEJMra025261]
14. **Bociąga-Jasik M**, Polus A, Góralska J, Czech U, Gruca A, Śliwa A, Garlicki A, Mach T, Dembińska-Kieć A. Metabolic effects of the HIV protease inhibitor--saquinavir in differentiating human preadipocytes. *Pharmacol Rep* 2013; **65**: 937-950 [PMID: 24145088]
15. **Gibellini L**, De Biasi S, Pinti M, Nasi M, Riccio M, Carnevale G, Cavallini GM, Sala de Oyanguren FJ, O'Connor JE, Mussini C, De Pol A, Cossarizza A. The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes. *AIDS* 2012; **26**: 2017-2026 [PMID: 22948272 DOI: 10.1097/QAD.0b013e328359b8be]
16. **Lo JC**, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. *Lancet* 1998; **351**: 867-870 [PMID: 9525364 DOI: 10.1016/S0140-6736(97)11443-X]
17. **Panse I**, Vasseur E, Raffin-Sanson ML, Staroz F, Rouveix E, Saiag P. Lipodystrophy associated with protease inhibitors. *Br J Dermatol* 2000; **142**: 496-500 [PMID: 10735957]
18. **Carr A**, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. *Lancet* 1999; **353**: 2093-2099 [PMID: 10382692 DOI: 10.1016/S0140-6736(98)08468-2]
19. **Dubé MP**, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. *Lancet* 1997; **350**: 713-714 [PMID: 9291911 DOI: 10.1016/S0140-6736(05)63513-1]
20. **Mori MA**, Thomou T, Boucher J, Lee KY, Lallukka S, Kim JK, Torriani M, Yki-Järvinen H, Grinspoon SK, Cypess AM, Kahn CR. Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. *J Clin Invest* 2014; **124**: 3339-3351 [PMID: 24983316 DOI: 10.1172/JCI73468]

**P-Reviewer:** Arriagada GL, Chen C, Ciotti M, Menendez-Arias L

**S-Editor:** Kong JX **L-Editor: E-Editor:**

**Specialty type:** Virology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Diverse anti-human immunodeficiency virus agents synergistically inhibit adipogenesis *in vitro.*** Although detailed processes remain elusive, anti-human immunodeficiency virus agents of different action mechanisms synergistically inhibit proliferation and differentiation of preadipocytes that are prepared from human subcutaneous fat depots as reported by Jones *et al*[1].



**Figure 2 Organization of adipose tissues.** Adipose tissues consist of parenchymal cells and non-parenchymal cells. Coordinated interactions of these two components are important for adipose tissue performance.